ArticleJournal of thrombosis and thrombolysis2026
Real-world data on Factor V Leiden in Sweden: A nationwide family study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the first nationwide real-world register-based family study of factor V Leiden (FVL). To determine number of diagnosed patients with FVL in Sweden and the associated risk for venous thromboembolism (VTE). The Swedish Multi-Generation Register was linked to the Swedish National patient register for the period 1964-2018. Patients with FVL (FVL heterozygotes or homozygotes) were linked to family members. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for VTE were calculated for individuals with FVL compared with relatives without FVL. Thrombophilia was defined as antiphospholipid antibodies, FVL, prothrombin G20210A mutation, deficiencies of antithrombin, protein C, and protein S. Among 149,808 individuals from 9,641 pedigrees, 11,367 [66.4% females] family members were diagnosed with FVL corresponding to around 0.1% of the Swedish population. Totally 5,757 (59.7%) of the 9,641 index cases (first diagnosed FVL case in pedigree) suffered from VTE, A total of 17,703 (11.8%) family members were affected by VTE. The aHR for VTE for FVL carriers was 9.23 (95%CI 8.92-9.55). After exclusion of 9,641 index cases aHR for VTE was 6.74 (95%CI6.24-7.28). The risk of VTE was dependent on number of thrombophilias present in a patient even after exclusion of index cases. One thrombophilia was associated with an aHR of 7.79 (95%CI7.26-8.36), two thrombophilias 14.71 (95%CI11.10-19.50), and three or more thrombophilias 18.99 (95%CI6.13-58.87). This nationwide real-world register-based family study indicates that FVL is underdiagnosed in Sweden. FVL is a risk factor for VTE in thrombophilic families in Sweden. Thrombophilia screening appears worthwhile.
Indexed as
Identifiers
42377678What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.